K 111

Drug Profile

K 111

Alternative Names: BM 170744

Latest Information Update: 19 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Roche Diagnostics
  • Developer Kowa
  • Class Antihyperglycaemics; Lauric acids; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hyperlipidaemia; Type 2 diabetes mellitus

Most Recent Events

  • 14 Jul 2006 Two studies have been added to the adverse events and Diabetes therapeutic trials sections ,
  • 15 Feb 2005 Phase-II clinical trials in Type-2 diabetes mellitus in Japan (PO)
  • 15 Feb 2005 Phase-II clinical trials in Type-2 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top